Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALLER THAN PD: Hydroxychloroquine in Early Parkinson's Disease
NCT06816810Phase 2Active, not recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine in Parkinson's disease (PD), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Treatment-related adverse events at 52 weeks and Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale Part III at 48 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06816810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816810.